Current timing of ICD implantation after myocardial infarction

After myocardial infarction (MI), the timing of an implantable cardioverter-defibrillator (ICD) can determine whether a patient is protected from sudden cardiac death or exposed to the risks of an unnecessary procedure. The central difficulty is not a simple choice between early and delayed implantation. It is the need to estimate arrhythmic risk while accounting for infarct evolution, ventricular recovery, revascularization, competing health problems and the goals of the patient.

Evidence has shifted from a largely uniform 40-day waiting period to a more selective approach informed by contemporary heart-failure therapy. Nevertheless, early implantation remains controversial in primary prevention, whereas surviving ventricular tachycardia or ventricular fibrillation creates a different and usually more urgent clinical problem.

This review examines the evidence, identifies when waiting may be unsafe or unnecessary, and considers how Australian referral pathways, funding and follow-up affect implementation.

Why implantation timing matters after infarction

An ICD treats ventricular arrhythmias; it does not reverse the underlying ischaemic injury or heart failure. After MI, electrically diseased scar and border-zone myocardium create the substrate for sustained ventricular tachycardia (VT) and ventricular fibrillation (VF). The risk changes over time: acute ischaemia and inflammation may provoke arrhythmia early, while scar maturation and ventricular remodelling influence later risk.

Timing therefore involves several separate questions. Has coronary revascularization been completed? Has guideline-directed medical therapy (GDMT) been given long enough to reveal the true left ventricular ejection fraction (LVEF)? Is the patient’s prognosis dominated by arrhythmic death or by another condition? A 40-day interval answers none of these by itself.

For focused reading, the journal’s arrhythmia special issues bring together relevant reviews and expert perspectives. Their value lies in showing where recommendations remain unsettled and where evidence has become more applicable to current GDMT.

The historical basis for waiting 40 days

The 40-day rule largely derives from a subgroup analysis of MADIT-II, which established a survival benefit for prophylactic ICDs in people with prior MI and LVEF of 30% or less. Very early implantation, within about one month, was associated with a counterintuitive increase in mortality. That observation supported a delay, but it was not a randomised comparison of implantation dates and remains vulnerable to differences in illness severity, revascularization status and follow-up.

Later trials, including MUSTT, reinforced the value of ICD therapy in selected patients with prior infarction, reduced LVEF and inducible ventricular arrhythmias. Guideline recommendations subsequently combined a 40-day post-MI interval with at least three months of GDMT before primary-prevention implantation. The intention was to avoid device exposure during early infarct change and to allow ventricular function to improve before prognosis was judged.

Those safeguards remain relevant. A severely reduced LVEF soon after MI may reflect stunned or hibernating myocardium rather than permanent dysfunction. Implanting before recovery is known can produce appropriate shocks without preventing death from progressive pump failure, while exposing the patient to complications and psychological effects. A blanket delay can also leave some patients unprotected during a high-risk interval.

How modern therapy changes risk assessment

Contemporary care can alter the trajectory assumed by older trials. Revascularization, renin-angiotensin system or neprilysin inhibition, evidence-based beta-blockade, mineralocorticoid-receptor antagonism, SGLT2 inhibitors and other GDMT may improve LVEF and clinical status over weeks to months. “Optimal medical therapy” should be active and planned, not used as a reason to omit follow-up or prolong an arbitrary delay.

A useful distinction is between waiting for infarct stability, allowing time for GDMT, and deciding that implantation is unlikely to benefit. The first two are clinical processes with endpoints; the third requires prognosis-based discussion. Repeat echocardiography, ambulatory rhythm monitoring and ECG assessment can refine risk, but none replaces LVEF, functional status and clinical judgement in guideline-based decisions.

Current review collections can help clinicians compare electrophysiological approaches with broader heart-failure management. In practice, a multidisciplinary review should integrate arrhythmic history, blood pressure, renal function, revascularization, GDMT tolerance and the likelihood of meaningful survival. Where conduction delay and LV dyssynchrony are present, cardiac resynchronisation therapy with defibrillation (CRT-D) may also need assessment; device selection should not become a reason to omit sudden-death protection.

When early implantation can be justified

Secondary prevention has the clearest case for prompt action. A survivor of VF or sustained VT caused by MI-related scar generally needs definitive risk assessment, revascularization when indicated and ICD implantation without a routine 40-day wait if the event was not fully reversible and survival beyond a meaningful period is expected. Acute ischaemia, transient arrhythmia and reversible triggers must first be separated from persistent substrate.

Selected primary-prevention patients may also merit implantation before 40 days. International guidance has opened this route for patients with severe LV dysfunction and advanced heart-failure symptoms despite GDMT, and for some patients with recurrent ventricular arrhythmias or other compelling arrhythmic evidence. The rationale is strongest when the burden of sudden death is high, revascularization is complete or not required, and competing mortality is low.

Early implantation should not be confused with implanting during unstable MI or before the patient has been stabilised. A temporary strategy may be considered in rare high-risk cases while awaiting definitive treatment, although external wearable defibrillators have limited evidence and variable local availability. For most patients, an early clinical decision and expedited specialist review are safer than improvised bridging therapy.

Revascularization, scar and competing risks

The infarct’s electrical signature matters as much as its size. Cardiac MRI with late gadolinium enhancement can identify non-viable myocardium and scar burden associated with VT. Signal-averaged ECG, T-wave alternans, ventricular dyssynchrony and ambulatory monitoring may add context, but their ability to replace EF-based criteria in routine post-MI decisions remains uncertain. A reassuring Holter result cannot exclude future sustained arrhythmia.

Revascularization can improve perfusion, ventricular function and the electrical environment, yet it does not abolish scar-related risk. Conversely, apparent viability on imaging does not guarantee a survival benefit from an ICD. These modalities are most useful when they clarify genuine uncertainty, not when used to postpone a clear secondary-prevention indication.

Competing risks are equally important. Post-MI patients may die from recurrent ischaemia, progressive heart failure, stroke, renal disease or other illness before an arrhythmia that an ICD could terminate. Frailty, cognition, renal function and personal goals should therefore enter the same discussion as EF and VT. Shared decision-making is part of selecting a device for whom the expected benefit exceeds procedural and long-term harms.

Australian pathways and practical constraints

Access in Australia is shaped by geography, funding and the organisation of specialist care. Major ICD centres in Melbourne, Sydney, Brisbane and Perth receive referrals from regional and remote areas, including large parts of northern and western Australia. Remote interrogation can support follow-up, but it does not remove the need for in-person assessment, lead or generator assessment, or urgent care where local services are distant.

Medicare rebates support specialist consultations and hospital treatment, but device implantation and follow-up can create substantial private-sector costs for privately insured patients. People without adequate cover may face barriers to an early procedure, while public-hospital scheduling adds another layer. Documenting clinical urgency is therefore more useful than treating a referral date as the implantation date.

State ambulance services, including NSW Ambulance, Queensland Ambulance Service and Ambulance Victoria, operate under different models, but defibrillation and resuscitation remain central in out-of-hospital VF. Local surveillance of survived cardiac arrest, including data linkage across regions, can strengthen estimates of arrhythmic risk. Culturally safe care, interpreter access and Aboriginal and Torres Strait Islander cardiovascular services are also important in ensuring that referral patterns reflect community need rather than proximity to a large hospital.

The TGA and Australian Register of Therapeutic Goods provide a national device-safety framework. In the Australian device market, hospital procurement affects generator and lead availability, so replacement planning must preserve compatibility when a platform is unavailable. Follow-up models increasingly use remote monitoring, but variable mobile coverage and digital access mean that in-person support must remain available. The open-access material published by Journal of Arrhythmia supports continuing education across these multidisciplinary teams.

A practical pathway for timely implantation

Before discharge, document the final coronary anatomy and revascularization plan, repeat LVEF after the acute changes have settled, review ECG and ventricular arrhythmia history, start or optimise GDMT, and record whether sudden cardiac death risk appears to exceed competing mortality. If VF or sustained VT has occurred, involve cardiac electrophysiology early and avoid treating the primary-prevention waiting period as if it applied to secondary prevention.

A structured reassessment should occur around 40 days and again after approximately three months of GDMT, with earlier review when EF remains severely reduced, symptoms are advanced or arrhythmias recur. Reassessment is not automatic implantation: renewed imaging, medication tolerance, functional capacity and patient priorities may change the recommendation. If implantation is deferred, the plan should specify who will review the patient, what will trigger earlier referral and how symptoms or sustained arrhythmia will be reported.

When an ICD is implanted, counselling should cover the possibility of appropriate and inappropriate shocks, device follow-up, generator replacement, lead complications and temporary driving restrictions under applicable state road rules. Coordination between cardiology, general practice, device clinics and regional services is particularly important after discharge. Clinicians should make implant timing an explicit component of post-MI care, document the clinical rationale for early or delayed implantation, and give every patient a clear plan for reassessment and urgent contact. Make the timing decision a documented, shared clinical action, with a named clinician responsible for follow-up.